波多细胞胰岛素样生长因子1受体抑制的相反后果
Jennifer A Hurcombe1, Fern Barrington1, Micol Marchetti1
1Bristol Renal, University of Bristol, Bristol, UK.
iScience
|May 6, 2024
概括
部分抑制胰岛素样生长因子1受体 (IGF1R) 在细胞中可能会防止损伤,而完全丧失是有害的. 这一发现为专性病提供了潜在的治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 胰岛素受体 (IR) 信号传递对脏的细胞功能至关重要.
- 胰岛素类生长因子1受体 (IGF1R) 在细胞生理学中发挥作用.
- 了解IGF1R的作用对于病研究至关重要.
研究的目的:
- 为了研究不同程度的IGF1R抑制在 podocytes的影响.
- 确定IGF1R对受体细胞存活率和压力下功能的影响.
- 探索部分IGF1R抑制在病中的治疗潜力.
主要方法:
- 基因操纵以实现近乎完全的IGF1R敲除和部分的IGF1R敲除.
- 在体内研究评估albuminuria.
- 实验室内研究评估细胞死亡和线粒体功能.
- 蛋白质组分析以确定下游分子变化.
主要成果:
- 在细胞中几乎完全的IGF1R淘汰导致白蛋白尿和细胞死亡.
- 部分IGF1R倒置保护了受体细胞免受多克索鲁比诱导的损伤.
- 几乎完全的IGF1R损失下调了线粒体呼吸复合体I和DNA修复蛋白.
- 部分IGF1R抑制提高了线粒体呼吸复合体表达的调节.
结论:
- 抑制IGF1R的水平决定了它对细胞健康的影响.
- 改变的线粒体功能与podocytes中的IGF1R水平有关.
- 部分IGF1R抑制显示了对专性脏疾病的治疗前景.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Hormones Regulating Blood Glucose
3.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318


